{
  "schema_version": "1.0",
  "type": "article",
  "title": "The Two-Drug Bet in Weight-Loss Injections",
  "url": "https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.md",
  "lang": "en",
  "date": "2026-10-14",
  "publish_at": "2026-10-14T08:00:00+08:00",
  "updated_at": "2026-10-14",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "EloraTZP",
    "eloralintide",
    "tirzepatide",
    "obesity",
    "clinical trials"
  ],
  "summary": "In a Phase 2 trial, Lilly added eloralintide to tirzepatide, gaining additional weight-loss potential but also facing higher rates of treatment discontinuation due to adverse events. Whether Phase 3 dose escalation and co-formulation can turn that efficacy into a product upgrade patients are willing to continue remains to be demonstrated.",
  "key_points": [],
  "facts": [],
  "sections": [
    "01 | A New Partner Must First Beat the Existing In-House Option",
    "02 | Another Column of Numbers Adds a Cost to the Upgrade",
    "03 | Another Pathway Adds Another Product-Development Test",
    "04 | A Co-Formulation Still Has to Clear the Tolerability Hurdle",
    "Conclusion | Worth Advancing, with Trade-Offs the Next Test",
    "References"
  ],
  "references": [
    {
      "title": "Lilly",
      "source": "EloraTZP Phase 2 results, trial design, efficacy-estimand footnote, adverse events, and Phase 3 development plans. September 30, 2026.",
      "date": "",
      "url": "https://lilly.gcs-web.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide"
    },
    {
      "title": "Aronne et al.",
      "source": "SURMOUNT-4. JAMA. 2024;331:38–48. Background research on treatment withdrawal and continuation, not an EloraTZP trial.",
      "date": "",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2812936"
    }
  ],
  "images": [
    {
      "alt": "Figure 1 | Mean weight reduction at week 48 in the same Phase 2 trial, in participants with type 2 diabetes and obesity or overweight. The 9 + 15 mg labels refer to the separate doses of the two drugs, which were injected separately in this trial; the pen shapes are illustrative only. The 23.3% and 14.8% figures are estimates under the assumption of continued treatment, a difference of 8.5 percentage points.",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence-en/figure-01.png"
    },
    {
      "alt": "Figure 2 | The 23.3% figure is estimated under the assumption that participants continued receiving the study treatment. The dashed line illustrates a statistical assumption, not an observed patient trajectory; the efficacy estimand is also not equivalent to calculating results only for completers.",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence-en/figure-02.png"
    },
    {
      "alt": "Figure 3 | Eloralintide acts on amylin receptors, while tirzepatide acts on GIP and GLP-1 receptors. This is an illustration of the pathways of action, not a complete diagram of signaling across organs. The value of using the two molecules together must still be assessed in human trials.",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence-en/figure-03.png"
    },
    {
      "alt": "Figure 4 | Dose escalation, tolerability, and continued follow-up need to be designed together. The optimized regimen remains to be validated. The staircase does not represent actual doses or an adjustment schedule and is not personal medication guidance.",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence-en/figure-04.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence-en/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-14）。The Two-Drug Bet in Weight-Loss Injections。https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.html",
  "disclaimer": "This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.",
  "translations": {
    "zh-Hant": "2026-10-14-eloratzp-weight-loss-tolerability-persistence.html"
  }
}